...
首页> 外文期刊>British Journal of Medicine and Medical Research >Subclinical Oral Bisphosphonate-related Osteonecrosis of the Jaw: Systematic Review of the Literature and an Additional Case
【24h】

Subclinical Oral Bisphosphonate-related Osteonecrosis of the Jaw: Systematic Review of the Literature and an Additional Case

机译:亚临床口服双膦酸盐相关的下颌骨坏死:文献和其他病例的系统评价

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Introduction: Bisphosphonate-related osteonecrosis of the jaw ( BRONJ ), which has few studies despite the increase in the number of cases published in the literature in the last decade, is a rare complication related to the use of oral bisphosphonates. The objectives of this study are to perform a systematic review of the literature on cases of osteonecrosis of jaw associated with the use of oral bisphosphonates in the treatment of osteoporosis and to identify the main clinical characteristics and risk factors related to the cases described in the literature. In addition, a case of subclinical osteonecrosis of jaw associated with the use of oral bisphosphonate for a short period of time was reported. Methods: A systematic review was conducted to identify cases of BRONJ among individuals using oral bisphosphonate. The survey included articles published in English from the period January 1950 to October 2016 in the PubMed and Cochraine databases. Results: 49 published articles were selected, totalling 284 patients diagnosed with BRONJ. The mean age of the patients was 72.68 years and 96% were female. Alendronate was the most prescribed bisphosphonate, being used by 88.08% of the patients and osteoporosis/osteopenia was the indication of the treatment in 95% of the cases. The median duration of therapy until diagnosis of osteonecrosis of jaw was 5.23 years; 12.38% were on corticosteroids use at diagnosis and 82% of the patients performed some dental procedure preceding the onset of lesions. The mandible was the site most affected (74.64% of the cases) and 57,81% of the cases were in stage 2 at diagnosis. The most frequent associated conditions were: hypertension, corticosteroid use rheumatoid arthritis and diabetes mellitus, and 28% of cases occurred during the first 3 years of therapy. Conclusion: Bisphosphonate-related osteonecrosis of the jaw is a rare disease which is associated with dental procedures and systemic conditions, and may occur at any time during therapy.
机译:简介:与双膦酸盐有关的颌骨坏死(BRONJ),尽管近十年文献报道的病例数有所增加,但研究很少,这是与口服双膦酸盐有关的罕见并发症。这项研究的目的是对与使用口服双膦酸盐治疗骨质疏松症有关的颌骨骨坏死病例进行系统的文献综述,并确定与文献中所述病例相关的主要临床特征和危险因素。此外,还报告了在短时间内使用口服双膦酸盐引起的亚临床颌骨坏死病例。方法:进行了系统的审查,以确定使用口服双膦酸盐的个人中BRONJ的病例。该调查包括从1950年1月至2016年10月在PubMed和Cochraine数据库中以英文发表的文章。结果:选取49篇发表的文章,总共284例被诊断为BRONJ的患者。患者的平均年龄为72.68岁,女性为96%。阿仑膦酸盐是处方最重的双膦酸盐,在88.08%的患者中使用,骨质疏松/骨减少症是95%病例的治疗指征。直到诊断为颌骨坏死的平均治疗时间为5.23年;诊断时使用皮质类固醇药物的比例为12.38%,并且82%的患者在病变发作之前进行了一些牙科手术。下颌骨是受影响最严重的部位(占病例的74.64%),诊断时处于第二阶段的病例为57.81%。最常见的相关疾病是:高血压,使用类固醇类风湿性关节炎和糖尿病,其中28%的病例发生在治疗的前3年。结论:双膦酸盐相关的颌骨坏死是一种罕见的疾病,与牙科手术和全身状况有关,并且可能在治疗期间的任何时间发生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号